



Courtesy of the Kitasato Institute archives

Terumo Corporation was founded in 1921 by several scientists and doctors, including Dr. Shibasaburo Kitasato, to produce clinical thermometers in Japan. These vital medical devices had previously been imported, until they were cut off as a consequence of World War I.

The lifelong spirit of Dr. Kitasato, whose achievements received global recognition, is found in his statement: "Scientists should never feel self-satisfaction doing advanced research; the true objective is for the results to be put to use, thereby contributing to society."

"Contributing to Society through Healthcare," is both Terumo's starting point and unchanging Group mission. Keeping Dr. Kitasato's spirit of innovation and challenge alive, we strive to bring outstanding innovation to medicine and enable the best possible care for patients.

Group Mission

Contributing to Society through Healthcare

We contribute to society by providing valued products and services in the healthcare market and by responding to the needs of patients and healthcare professionals.

Core Values

Respect – Appreciative of others

We show respect and appreciation toward associates, customers, and business partners.

We value individuality and diverse cultures, and listen widely and carefully to different opinions and the voice of society.

Integrity – Guided by our mission

As associates of Terumo Group, responsible for life and health, we always act with sincerity and a sense of mission.

Through our daily efforts, we build trust among all stakeholders.

Care – Empathetic to patients

We are mindful that everything we do ultimately connects us to patients.

We strive to understand health providers deeply and work together with them to give patients a better future.

Quality – Committed to excellence

To ensure safety and reliability in healthcare, we view each issue from a "gemba" perspective in order to find the optimal solution.

As well as product quality, we pursue excellence in all we do, from product supply to customer care.

Creativity – Striving for innovation

We promote a mindset that embraces challenge for the future, and work with curiosity and passion.

We respond to the needs of "gemba" by delivering products and services that create meaningful value in a timely manner.

Contents

Group Mission

Core Values

2 Message from the President and CEO

Strategy

8 Targets and Fiscal 2019 Performance by Company

10 Message from the CAFO

12 Companies at a Glance

14 Strategies by Company

14 Cardiac and Vascular Company

18 General Hospital Company

22 Blood and Cell Technologies Company

26 R&D and Intellectual Property

29 Production and Supply

30 Human Resource Strategy

Governance and Compliance

32 Sustainability

34 Corporate Governance

34 Dialogue between Independent Directors

47 Compliance

49 Digital Governance

50 Risk Management

52 Directors, Audit and Supervisory Committee Members,
and Executive Officers

Financial Information

55 Five-Year Financial Summary

56 Financial Review

58 Consolidated Financial Statements

64 Corporate Information

Editorial Policy

Terumo prepares communication tools to provide stakeholders with straightforward reporting on the business activities it is pursuing in fulfillment of its Group mission—"Contributing to Society through Healthcare"—and to promote communication with society. Terumo reports provide information on the Company's primary business activities and results with a focus on explanations of its Mid- to Long-term Growth Strategy. In addition, we also publish sustainability data books to provide information on how we are helping to build a sustainable society by reducing our environmental impact and contributing to society.

Coverage

Report coverage includes to the extent possible those elements of the global Terumo Group falling within the scope of consolidated earnings statements.

Coverage, however, differs in certain instances.

Adoption of International Financial Reporting Standards

Beginning with its financial results announcement for fiscal 2017, the Company has adopted International Financial Reporting Standards (IFRS) with the goal of making its financial information more easily comparable to that of companies around the world and to improve management accuracy and strengthen corporate governance through the global application of uniform rules.

In fiscal 2020, the name of the Blood Management Company was changed to the Blood and Cell Technologies Company. This change is purely a change in name and does not impact segment information. Accordingly, the new name is also used for references pertaining to fiscal 2019.